THE Translational Research Institute's (TRI) new Brisbane facility, ENTRI, has secured its first tenant in the global healthcare company Sanofi.
As the biomedical manufacturing complex nears completion, the signing marks an important milestone for Qld, with Sanofi's presence at ENTRI part of an expansion for the Translational Science Hub connecting researchers with the company's scientists in France and the US.
Sanofi's presence will help stimulate the local biomedical sector through their expertise in product development, clinical research and commercialisation.
Jointly funded by the Queensland Government and TRI, ENTRI is due to open in early 2026, providing dedicated access to cGMP cleanrooms, wet labs, plus office and collaboration space for clinical trial product manufacture.
TRI CEO Professor Mahar Gandhi said he hopes to see in-house clinical trials being conducted from therapeutics that have been discovered and developed at ENTRI.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Nov 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Nov 25
